{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T12:41:02Z","timestamp":1748695262817},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1245\/s10434-019-07595-2","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T15:02:50Z","timestamp":1563980570000},"page":"3389-3396","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing"],"prefix":"10.1245","volume":"26","author":[{"given":"Jenny","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirivan","family":"Seng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Equivel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon S.","family":"Lum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"7595_CR1","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1126\/science.2270482","volume":"250","author":"J Hall","year":"1990","unstructured":"Hall J, Lee M, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990;250:1684\u20139.","journal-title":"Science"},{"key":"7595_CR2","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1126\/science.8091231","volume":"265","author":"R Wooster","year":"1994","unstructured":"Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265:2088\u201390.","journal-title":"Science"},{"key":"7595_CR3","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","volume":"372","author":"DF Easton","year":"2015","unstructured":"Easton DF, Pharoah PD, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015;372:2243\u201357.","journal-title":"N Engl J Med"},{"key":"7595_CR4","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1245\/s10434-017-5963-7","volume":"24","author":"E O\u2019Leary","year":"2017","unstructured":"O\u2019Leary E, Iacoboni D, Holle J, et al. Expanded gene panel use for women with breast cancer: identification and intervention beyond breast cancer risk. Ann Surg Oncol. 2017;24:3060\u20136.","journal-title":"Ann Surg Oncol"},{"key":"7595_CR5","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1245\/s10434-018-6621-4","volume":"25","author":"S Yang","year":"2018","unstructured":"Yang S, Axilbund JE, O\u2019Leary E, et al. Underdiagnosis of hereditary breast and ovarian cancer in medicare patients: genetic testing criteria miss the mark. Ann Surg Oncol. 2018;25:2925\u201331.","journal-title":"Ann Surg Oncol"},{"key":"7595_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.18.01631","volume":"37","author":"PD Beitsch","year":"2019","unstructured":"Beitsch PD, Whitworth PW, Hughes K, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2019;37:453\u201360.","journal-title":"J Clin Oncol"},{"key":"7595_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"7595_CR8","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamaoncol.2018.0644","volume":"4","author":"AW Kurian","year":"2018","unstructured":"Kurian AW, Ward KC, Hamilton AS, et al. Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer. JAMA Oncol. 2018;4:1066\u201372.","journal-title":"JAMA Oncol"},{"key":"7595_CR9","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1186\/s12885-015-1934-1","volume":"15","author":"BK Eccles","year":"2015","unstructured":"Eccles BK, Copson E, Maishman T, Abraham JE, Eccles DM. Understanding of BRCA VUS genetic results by breast cancer specialists. BMC Cancer. 2015;15:936.","journal-title":"BMC Cancer"},{"key":"7595_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/cge.12563","volume":"88","author":"CL Scherr","year":"2015","unstructured":"Scherr CL, Lindor NM, Malo TL, Couch FJ, Vadaparampil ST. Genetic counselors\u2019 practices and confidence regarding variant of uncertain significance results and reclassification from BRCA testing. Clin Gen. 2015;88:523\u20139.","journal-title":"Clin Gen"},{"key":"7595_CR11","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1093\/annonc\/mdv278","volume":"26","author":"DM Eccles","year":"2015","unstructured":"Eccles DM, Mitchell G, Monteiro AN, et al. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. Ann Oncol. 2015;26:2057\u201365.","journal-title":"Ann Oncol"},{"key":"7595_CR12","unstructured":"Genetic\/Familial High-Risk Assessment: Breast and ovarian. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf . Accessed 21 Apr 2019."},{"key":"7595_CR13","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/000313481508101006","volume":"81","author":"DR Howarth","year":"2015","unstructured":"Howarth DR, Lum SS, Esquivel P, Garberoglio CA, Senthil M, Solomon NL. Initial results of multigene panel testing for hereditary breast and ovarian cancer and lynch syndrome. Am Surg. 2015;81:941\u20134.","journal-title":"Am Surg"},{"key":"7595_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1200\/JCO.18.01952","volume":"37","author":"KJ Milliron","year":"2019","unstructured":"Milliron KJ, Griggs JJ. Advances in genetic testing in patients with breast cancer, high-quality decision making, and responsible resource allocation. J Clin Oncol. 2019;37:445\u20137.","journal-title":"J Clin Oncol"},{"key":"7595_CR15","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1200\/JCO.2016.71.6480","volume":"35","author":"AW Kurian","year":"2017","unstructured":"Kurian AW, Li Y, Hamilton AS, et al. Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. J Clin Oncol. 2017;35:2232\u20139.","journal-title":"J Clin Oncol"},{"key":"7595_CR16","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1245\/s10434-017-5959-3","volume":"24","author":"JL Welsh","year":"2017","unstructured":"Welsh JL, Hoskin TL, Day CN, et al. Clinical decision-making in patients with variant of uncertain significance in BRCA1 or BRCA2 genes. Ann Surg Oncol. 2017;24:3067\u201372.","journal-title":"Ann Surg Oncol"},{"key":"7595_CR17","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jamcollsurg.2017.12.037","volume":"226","author":"HJ Pederson","year":"2018","unstructured":"Pederson HJ, Gopalakrishnan D, Noss R, Yanda C, Eng C, Grobmyer SR. Impact of multigene panel testing on surgical decision making in breast cancer patients. J Am Coll Surg. 2018;226:560\u20135.","journal-title":"J Am Coll Surg"},{"key":"7595_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10549-018-5057-7","volume":"174","author":"DA Henry","year":"2019","unstructured":"Henry DA, Lee MC, Almanza D, et al. Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE). Breast Cancer Res Treat. 2019;174:39\u201345.","journal-title":"Breast Cancer Res Treat"},{"key":"7595_CR19","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1245\/s10434-017-5976-2","volume":"24","author":"E Gilbert","year":"2017","unstructured":"Gilbert E, Zabor EC, Stempel M, Mangino D, Heerdt A, Pilewskie M. Differences among a modern cohort of BRCA mutation carriers choosing bilateral prophylactic mastectomies compared to breast surveillance. Ann Surg Oncol. 2017;24:3048\u201354.","journal-title":"Ann Surg Oncol"},{"key":"7595_CR20","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1245\/s10434-016-5408-8","volume":"23","author":"JC Boughey","year":"2016","unstructured":"Boughey JC, Attai DJ, Chen SL, et al. Contralateral prophylactic mastectomy consensus statement from the American Society of Breast Surgeons: additional considerations and a framework for shared decision making. Ann Surg Oncol. 2016;23:3106\u201311.","journal-title":"Ann Surg Oncol"},{"key":"7595_CR21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1245\/s10434-016-5688-z","volume":"24","author":"KK Hunt","year":"2017","unstructured":"Hunt KK, Euhus DM, Boughey JC, et al. Society of surgical oncology breast disease working group statement on prophylactic (risk-reducing) mastectomy. Ann Surg Oncol. 2017;24:375\u201397.","journal-title":"Ann Surg Oncol"},{"key":"7595_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1001\/jama.2018.18942","volume":"321","author":"SM Domchek","year":"2019","unstructured":"Domchek SM. Risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers: a complex discussion. JAMA. 2019;321:27.","journal-title":"JAMA"},{"key":"7595_CR23","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1056\/NEJMoa012158","volume":"346","author":"TR Rebbeck","year":"2002","unstructured":"Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616\u201322.","journal-title":"N Engl J Med"},{"key":"7595_CR24","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/jamaoncol.2015.0658","volume":"1","author":"K Metcalfe","year":"2015","unstructured":"Metcalfe K, Lynch HT, Foulkes WD, et al. Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol. 2015;1:306\u201313.","journal-title":"JAMA Oncol"},{"key":"7595_CR25","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2018.13152","volume":"320","author":"J Mersch","year":"2018","unstructured":"Mersch J, Brown N, Pirzadeh-Miller S, et al. Prevalence of variant reclassification following hereditary cancer genetic testing. JAMA. 2018;320:1266\u201374.","journal-title":"JAMA"},{"key":"7595_CR26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10689-015-9788-x","volume":"14","author":"MR Wevers","year":"2015","unstructured":"Wevers MR, Schmidt MK, Engelhardt EG, et al. Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1\/2 mutation: retrospective data from the Dutch HEBON study. Fam Cancer. 2015;14:355\u201363.","journal-title":"Fam Cancer"},{"key":"7595_CR27","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1001\/jama.2018.5330","volume":"319","author":"J Gill","year":"2018","unstructured":"Gill J, Obley AJ, Prasad V. Direct-to-consumer genetic testing: the implications of the US FDA\u2019s first marketing authorization for BRCA mutation testing. JAMA. 2018;319:2377\u20138.","journal-title":"JAMA"},{"key":"7595_CR28","unstructured":"23andMe. https:\/\/www.23andme.com\/?mdb1=true . Accessed 21 Apr 2019."},{"key":"7595_CR29","unstructured":"color. https:\/\/www.color.com\/ . Accessed 21 Apr 2019."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07595-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-019-07595-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07595-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T05:57:45Z","timestamp":1610603865000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-019-07595-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["7595"],"URL":"https:\/\/doi.org\/10.1245\/s10434-019-07595-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,24]]},"assertion":[{"value":"22 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report no financial disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}